I have worked in clinical/ translational research in lung cancer for more than 25 years. In 2018, I became the Executive Director for the Center for Thoracic Oncology, at Tisch Cancer Institute at Mount Sinai Health System and Professor of Medicine and Pathology at the Icahn School of Medicine, Mount Sinai, NY. My current research is in biomarker developments for early detection, and treatment of lung cancer. I am studying biomarkers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment.
My laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe in lung cancer. Of recent interest is the evaluation of immune checkpoint biomarkers for immunotherapy. I have led several efforts to perform comparisons of commercial antibodies, assays and staining platforms for PD-L1 expression (“Blueprint Study”). My laboratory has developed, optimized and validated expression assays including IHC, SISH, CISH, mRNA ISH and PDA for a wide variety of novel and existing targets in support of large and small clinical studies as well as basic research projects. I have also led several clinical trials as PI/Co-PI, among them studies, which has led to FDA approval, such as Etoposide for SCLC and Necitumumab for NSCLC. Over about 20 years I have been Project PI/co-PI for several projects in the NCI- sponsored Colorado Lung SPORE (Special Programs of Research Excellence) program (P50), and PI for the NCIsponsored SPECS (Strategic Partnering to Evaluate Cancer Signatures (U-01, PAR-10-126/11-151). I have published > 450 peer-reviewed scientific articles.
Ongoing and recently completed projects that I would like to highlight include:
U54 CA 260560-01 (SeroNet) NIH/NCI
Vulnerability of SARS-CoV-2 Infection in Lung Cancer based on Serological Antibody Analyses.
International Association for the Study of Lung Cancer
IASLC Staging Project